Noviocell BV is a highly innovative biotech company. It focuses on the development of the first ever synthetic solution for 3D cell culturing, ranging from organoid growth to personalized medicine.
Noviocell will build upon its proprietary polyisocyanopeptide (PIC) hydrogel technology and develop them into easy-to-use solutions for biomedical researchers, biotech and pharma industry and clinicians. The PIC hydrogels are based on breakthrough research from the internationally highly rated Institute for Molecules and Materials at Radboud University, which has resulted in high-impact publications (Nature, Nature Material and Nature communications).
The potential of 3D cell culturing is evident: never before have we been able to assess the complexity of (human) biology in such a detailed manner. Recent highlights include brain, liver and disease-specific organoids (which especially have shown tremendous value in combination with gene editing technology such as CRISPR/CAS). These will contribute to our understanding of health and disease as well as identification of new therapeutic targets and biomarkers. But to fully leverage the potential of 3D cell culturing it is necessary to address three key bottlenecks: robustness, scalability and clinical use.
The most commonly used matrices are from animal origin. This leads to batch-to-batch variability resulting in inconsistencies in results. Noviocell will build upon its synthetic PIC hydrogels and develop them into easy-to-use solutions. The unique combination of tunable biofunctionality and biomechanics of the PIC hydrogel makes it an excellent matrice for 3D cell culture or regenerative medicine.
Noviocell is partner in projects and receives funding of several funds.
Noviocell has received Early Phase Financing (VFF) from RVO. More information click here.
Noviocell has received a proof of principle subsidy of LBDF. More information click here.